علاج جدري الماء في نقص المناعة الأولي، العلاج الكيميائي المثبط للمناعة، أو العلاج الإشعاعي

References

DOI: 10.1016/j.jinf.2008.03.004

Patients in the categories shown in Table 2 should be considered as being at risk of severe VZV infection, and should receive antiviral therapy as soon as possible.

Patients with severe primary immunodeficiency such as Severe Combined Immunodeficiency (SCID) or Wiskotte Aldrich syndrome.

All patients receiving immunosuppressive chemotherapy or radiotherapy for malignant disease, up to 6 months after completion of treatment.

All patients on immunosuppressive therapy following a solid organ transplant.

All patients who have undergone bone marrow transplantation, up to 12 months after completing all immunosuppressive therapy, or longer if graft versus host disease has occurred.

Patients receiving other immunomodulatory drugs such as azathioprine, cyclosporine, methotrexate, cyclophosphamide and the cytokine inhibitors, and/or chronic low dose steroid therapy.

Patients with HIV infection, particularly if the CD4 count is less than 200 cells/mm3.

Early assessment in hospital is recommended, as parenteral treatment is most appropriate to prevent complications.

Aciclovir at a dose of 10 mg/kg intravenously every 8 h should be used for those who have or are at risk of severe disease.

Two weeks therapy may be appropriate in severe disease or in the immunocompromised, for whom intravenous therapy is usually recommended, although with rapid improvement an early switch to oral therapy may be considered.

Switch to oral therapy as soon as possible.